A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

R Hájek, T Masszi, M T Petrucci, A Palumbo, L Rosiñol, A Nagler, K L Yong, A Oriol, J Minarik, L Pour, M A Dimopoulos, V Maisnar, D Rossi, H Kasparu, J Van Droogenbroeck, D B Yehuda, I Hardan, M Jenner, M Calbecka, M Dávid, J de la Rubia, J Drach, Z Gasztonyi, S Górnik, X Leleu, M Munder, M Offidani, N Zojer, K Rajangam, Y-L Chang, J F San-Miguel, H Ludwig
  • Leukemia, June 2016, Nature Publishing Group
  • DOI: 10.1038/leu.2016.176
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Albert Oriol